scholarly journals Gene Screening of Astrocytoma Grade III Relative to Grade II via Network Analysis: A New Molecular Insight

2018 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Mostafa Rezaei-Tavirani ◽  
Sina Rezaei Tavirani
Keyword(s):  
Network Analysis ◽  
Gene Screening ◽  
Grade Ii ◽  
Astrocytoma Grade Iii ◽  
Grade Iii ◽  
Astrocytoma Grade

scholarly journals NI-6 Preoperative differential diagnosis of grade II and grade III in cases with astrocytoma, IDH mutant

2021 ◽  
Vol 3 (Supplement_6) ◽  
pp. vi18-vi19
Author(s):  
Hirohito Yano ◽  
Kazuhiro Miwa ◽  
Noriyuki Nakayama ◽  
Takashi Maruyama ◽  
Naoyuki Ohe ◽  
...  
Keyword(s):  
Resonance Spectroscopy ◽  
Contrast Effects ◽  
Distribution Map ◽  
Positron Emission ◽  
Wide Range ◽  
Grade Ii ◽  
Supratentorial Glioma ◽  
Normal Cortex ◽  
Grade Iii ◽  
Astrocytoma Grade

Abstract Purpose: We attempted to differentiate between IDH-mutant astrocytoma Grade II and grade III by using methionine (MET) positron emission tomography (PET) and magnetic resonance spectroscopy (MRS). Subjects and Methods: We retrospectively analyzed 41 adult supratentorial glioma cases with confirmed histological diagnosis and IDH status from June 2015 to June 2020. These included 21 males, with an average age of 38.5 years (19–59 years), including seven astrocytoma grade II (A-II) and 34 grade III (A-III) cases. We determined the accumulation value rate of the maximum tumor to normal cortex accumulation value (T/N ratio) in MET-PET. We obtained the peak ratios of N-acetyl aspartate (NAA)/ creatine (Cr), choline (Cho)/Cr, and Cho/NAA. We investigated the correlation between the T/N ratios and MRS parameters and examined the contrast effects on MRI. Results: There were no significant differences in the T/N ratio and MRS parameters between A-IIs and A-IIIs. Only Cho/NAA ratios were significantly correlated with the T/N ratios (r = 0.443, P = 0.0037). We divided the distribution map into four areas with the highest T/N ratio of AII (1.59) and the highest Cho/NAA ratio (3.66). That is, 1) T/N ratio ≤ 1.59 & Cho/NAA ≤ 3.66, 2) >1.59 & ≤ 3.66, 3) ≤1.59 & > 3.66, 4) &gt 1.59 & &gt 3.66. The diagnostic rates for A-III were 1) 61.1% (11/18), 2) 100% (7/7), 3) 100% (9/9), and 4) 100% (7/7). We found the contrast effects in only 7 cases (20.6%) of A-III, which were distributed in areas 2) to 4). Conclusion: A-IIs and A-IIIs distributed in area 1) were difficult to distinguish, and they need careful observation as a step before the transition to areas 2)-4). Meanwhile, A-IIIs reaching widespread distribution to areas 2)-4) because of their wide range of malignancies require clinically aggressive treatment. The method might be beneficial in grade analysis of IDH-mutant astrocytomas.

Treatment of astrocytoma grade III with Photofrin II as a radiosensitizer

2013 ◽  
Vol 189 (11) ◽  
pp. 972-976 ◽  
Author(s):  
M. Schaffer ◽  
A. Hofstetter ◽  
B. Ertl-Wagner ◽  
R. Batash ◽  
J. Pöschl ◽  
...  
Keyword(s):  
Photofrin Ii ◽  
Astrocytoma Grade Iii ◽  
Grade Iii ◽  
Astrocytoma Grade

scholarly journals Plasma-Derived Extracellular Vesicles Reveal Galectin-3 Binding Protein as Potential Biomarker for Early Detection of Glioma

2021 ◽  
Vol 11 ◽  
Author(s):  
Rashmi Rana ◽  
Kirti Chauhan ◽  
Poonam Gautam ◽  
Mahesh Kulkarni ◽  
Reema Banarjee ◽  
...  
Keyword(s):  
Early Detection ◽  
Brain Tumors ◽  
Blood Plasma ◽  
Extracellular Vesicles ◽  
Binding Protein ◽  
Potential Biomarker ◽  
Galectin 3 ◽  
Grade Ii ◽  
Grade Iii ◽  
Astrocytoma Grade

Gliomas are the most common type of the malignant brain tumor, which arise from glial cells. They make up about 40% of all primary brain tumors and around 70% of all primary malignant brain tumors. They can occur anywhere in the central nervous system (CNS) and have a poor prognosis. The average survival of glioma patients is approximately 6–15 months with poor aspects of life. In this edge, identification of proteins secreted by cancer cells is of special interest because it may provide a better understanding of tumor progression and provide early diagnosis of the diseases. Extracellular vesicles (EVs) were isolated from pooled plasma of healthy controls (n=03) and patients with different grades of glioma (Grade I or II or III, n=03 each). Nanoparticle tracking analysis, western blot, and flow cytometry were performed to determine the size, morphology, the concentration of glioma-derived vesicles and EV marker, CD63. Further, iTRAQ-based LC-MS/MS analysis of EV protein was performed to determine the differential protein abundance in extracellular vesicles across different glioma grades. We further verified galectin-3 binding protein (LGALS3BP) by ELISA in individual blood plasma and plasma-derived vesicles from control and glioma patients (n=40 each). Analysis by Max Quant identified 123 proteins from the pooled patient exosomes, out of which 34, 21, and 14 proteins were found to be differentially abundant by more than 1.3-fold in the different grades of glioma grade I, pilocytic astrocytoma; grade II, diffuse astrocytoma; grade III, anaplastic astrocytoma, respectively, in comparison with the control samples. A total of seven proteins—namely, CRP, SAA2, SERPINA3, SAA1, C4A, LV211, and KV112—showed differential abundance in all the three grades. LGALS3BP was seen to be upregulated across the different grades, and ELISA analysis from individual blood plasma and plasma-derived extracellular vesicles confirmed the increased expression of LGALS3BP in glioma patients (p<0.001). The present study provides LGALS3BP as a potential biomarker for early detection of glioma and improve survival outcome of the patient. The present study further provides the information of progression and monitoring the tumor grades (grade 1, grade II, grade III).

scholarly journals Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients

2019 ◽  
Vol 7 (21) ◽  
pp. 3514-3520
Author(s):  
Mohanad Mundher Abdulghani ◽  
Mohamad Natiq Abbas ◽  
Wafaa Redha Mohammed
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Immunohistochemical Expression ◽  
Astrocytic Tumours ◽  
Grade Ii ◽  
Epidermal Growth ◽  
Grade Iii ◽  
Astrocytoma Grade

BACKGROUND: Diffuse astrocytomas constitute the largest group of primary malignant human intracranial tumours. They are classified by the World Health Organization (WHO) into three histological malignancy grades: diffuse astrocytomas (grade II), anaplastic astrocytomas (grade III) and glioblastoma (grade IV) based on histopathological features such as cellular atypia, mitotic activity, necrosis and microvascular proliferation. Epidermal growth factor receptor (EGFR) is a 170-kDa transmembrane tyrosine kinase receptor expressed in a variety of normal and malignant cells regulating critical cellular processes. When activated, epidermal growth factor receptor (EGFR) triggers several signalling cascades leading to increased proliferation and angiogenesis and decreased apoptosis and hence associated with aggressive progression of the tumour. Epidermal growth factor receptor (EGFR) level is known to be a strong indicator associated with the aggressive behaviour of the tumour and acts as a prognostic factor for evaluating the survival rate. AIM: To evaluate the expression of epidermal growth factor receptor (EGFR) in different grades of astrocytoma. MATERIAL AND METHODS: formalin-fixed paraffin-embedded astrocytic tumours of 44 patients were collected from the archival material of pathology department of Ghazi Al Hariri Teaching Hospital during the period from June to December 2018. Hematoxylin and eosin-stained sections were used to characterise the tumours histologically based on cellularity, nuclear hyperchromasia, polymorphism, mitotic activity, vascular proliferation and necrosis with or without pseudopallisading of tumour cells. Diagnosis and grading of astrocytic tumours in this study were made according to WHO criteria (2016). Using a monoclonal antibody to the epidermal growth factor receptor (EGFR) and immunohistochemical analysis, the expression and distribution of epidermal growth factor receptor in astrocytic tumours were examined. RESULTS: The study included 1 case pilocytic astrocytoma (grade I), 20 cases diffuse astrocytoma (grade II), 5 cases anaplastic astrocytoma (grade III) and 18 cases of glioblastoma (grade IV). Expression of EGFR was found in 38.88% of the glioblastoma samples (grade IV). However, none of the astrocytomas of WHO grades I, II and III showed immunoreactivity for EGFR protein. Different patterns of immunoreactive cells and significant intratumor heterogeneity of EGFR expression were observed in glioblastomas. CONCLUSION: The immunohistochemical expression of Epidermal growth factor receptor (EGFR) was restricted only to high-grade astrocytic tumours, namely glioblastoma, thus may use to predict glioblastoma.

scholarly journals Hypermethylation of the Promoter of miR-338-5p Mediates Aberrant Expression of ETS-1 and Is Correlated With Disease Severity Of Astrocytoma Patients

2021 ◽  
Vol 11 ◽  
Author(s):  
Junping Wang ◽  
Cheng Huo ◽  
Jinzhu Yin ◽  
Lixia Tian ◽  
Lili Ma ◽  
...  
Keyword(s):  
Disease Severity ◽  
Dna Methyltransferase ◽  
Diffuse Astrocytoma ◽  
Specific Sequence ◽  
Aberrant Expression ◽  
Astrocytoma Cell ◽  
Grade Ii ◽  
Astrocytoma Grade Iii ◽  
Astrocytoma Grade

The pro-oncogene ETS-1 (E26 transformation-specific sequence 1) is a key regulator of the proliferation and invasion of cancer cells. The present work examined the correlation of the aberrant expression of ETS-1 with histological or clinical classification of astrocytoma: grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), and grade IV (glioblastoma multiforme). MicroRNA, miR-338-5p, was predicted by an online tool (miRDB) to potentially target the 3’ untranslated region of ETS-1; this was confirmed by multi-assays, including western blot experiments or the point mutation of the targeting sites of miR-338-5p in ETS-1’s 3’untralation region (3’UTR). The expression of miR-338-5p was negatively associated with that of ETS-1 in astrocytoma, and deficiency of miR-338-5p would mediate aberrant expression of ETS-1 in astrocytoma. Mechanistically, hypermethylation of miR-338-5p by DNA methyltransferase 1 (DNMT1) resulted in repression of miR-338-5p expression and the aberrant expression of ETS-1. Knockdown or deactivation of DNMT1 decreased the methylation rate of the miR-338-5p promoter, increased the expression of miR-338-5p, and repressed the expression of ETS-1 in astrocytoma cell lines U251 and U87. These results indicate that hypermethylation of the miR-338-5p promoter by DNMT1 mediates the aberrant expression of ETS-1 related to disease severity of patients with astrocytoma.

Withdrawn: Intraoperative Sono-photodynamic Therapy for Anaplastic Astrocytoma Grade III With Transformation in Glioblastoma Grade IV

2017 ◽  
Vol 04 ◽  
Author(s):  
Dmitry Tzerkovsky ◽  
Fedor Borichevsky ◽  
Yuri Grachev ◽  
Yuri Istomin
Keyword(s):  
Photodynamic Therapy ◽  
Anaplastic Astrocytoma ◽  
Cancer Drugs ◽  
Clinical Cancer ◽  
Astrocytoma Grade Iii ◽  
Grade Iii ◽  
Astrocytoma Grade ◽  
Copyright Permission ◽  
Legal Right

The following article has been withdrawn on the request of the editor of the journal Clinical Cancer Drugs: Title: Intraoperative Sono-photodynamic Therapy for Anaplastic Astrocytoma Grade III with Transformation in Glioblastoma Grade IV Authors: Dmitry Tzerkovsky*, Fedor Borichevsky, Yuri Grachev, Yuri Istomin Bentham Science apologizes to the readers of the journal for any inconvenience this may cause Bentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

Ten-year survival among patients with supratentorial astrocytomas grade III and IV

1988 ◽  
Vol 69 (4) ◽  
pp. 506-509 ◽  
Author(s):  
Leif G. Salford ◽  
Arne Brun ◽  
Sigrid Nirfalk
Keyword(s):  
Tumor Recurrence ◽  
Good Condition ◽  
Central Nervous System Tumors ◽  
Common Denominator ◽  
Southern Sweden ◽  
Content Type ◽  
Swedish Cancer Registry ◽  
Astrocytoma Grade Iii ◽  
Grade Iii ◽  
Astrocytoma Grade

✓ The Swedish Cancer Registry, in a linkage with the Swedish Registry of Statistics, was used to trace all patients operated on in Southern Sweden for histopathologically verified malignant primary central nervous system tumors during the years 1958 to 1975. Patients surviving 10 years after the operation were identified, and their original surgical specimens were reexamined. Six (0.5%) of 1147 patients were shown to have survived for between 12 and 28 years after surgery for supratentorial astrocytomas grade III and IV. All six patients are in good condition, without signs of tumor recurrence. The only obvious common denominator for the survivors is their youth at operation. Three patients were 7 to 11 years old at surgery, and none was older than 38 years. It is concluded that a cure may be possible in exceptional patients with the “incurable” astrocytoma grade III and IV.

scholarly journals Aquaporin Positron Emission Tomography Differentiates Between Grade III and IV Human Astrocytoma

Neurosurgery ◽  
2017 ◽  
Vol 82 (6) ◽  
pp. 842-846 ◽  
Author(s):  
Yuji Suzuki ◽  
Yukihiro Nakamura ◽  
Kenichi Yamada ◽  
Satoshi Kurabe ◽  
Kouichirou Okamoto ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Pet Imaging ◽  
Tumor Grade ◽  
Emission Tomography ◽  
Standardized Uptake Values ◽  
Positron Emission ◽  
Microvascular Proliferation ◽  
Astrocytoma Grade Iii ◽  
Grade Iii ◽  
Astrocytoma Grade

Abstract BACKGROUND Aquaporin (AQP) water channels play a significant role in mesenchymal microvascular proliferation and infiltrative growth. AQPs are highly expressed in malignant astrocytomas, and a positive correlation is observed between their expression levels and histological tumor grade. OBJECTIVE To examine the utility of aquaporin positron emission tomography (PET) for differentiating between astrocytoma grade III and grade IV using the AQP radioligand [11C]TGN-020. METHODS Fifteen astrocytoma patients, grade III (n = 7) and grade IV (n = 8), and 10 healthy volunteers underwent [11C]TGN-020 aquaporin PET imaging. Surgical tissues of astrocytoma patients were examined for histopathological grading using the WHO classification standard and expression of AQP1 and AQP4 immunohistochemically. RESULTS Mean standardized uptake values of astrocytoma grade III and IV (0.51 ± 0.11 vs 1.50 ± 0.44, respectively) were higher than normal white matter (0.17 ± 0.02, P < .001) for both tumor grades. Importantly, mean standardized uptake values of astrocytoma grade IV were significantly higher than grade III (P < .01). CONCLUSION Our study demonstrated that [11C]TGN-020 aquaporin PET imaging differentiated between astrocytoma grades III and IV. We suggest its clinical application as a noninvasive diagnostic tool would lead to advancements in the management of these malignant brain tumors.

Astrocytoma Grade III Associated with Profuse Subarachnoid Bleeding as Its First Manifestation

1951 ◽  
Vol 8 (2) ◽  
pp. 236-239 ◽  
Author(s):  
Richard L. DeSaussure ◽  
Charles D. Scheibert ◽  
Louis A. Hazouri
Keyword(s):  
Subarachnoid Bleeding ◽  
Astrocytoma Grade Iii ◽  
Grade Iii ◽  
Astrocytoma Grade
Sign in / Sign up

Export Citation Format

Share Document